These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34278936)

  • 21. Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy.
    Clarke WA; Chatelut E; Fotoohi AK; Larson RA; Martin JH; Mathijssen RHJ; Salamone SJ
    Eur J Cancer; 2021 Nov; 157():428-440. PubMed ID: 34597977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
    Paci A; Veal G; Bardin C; Levêque D; Widmer N; Beijnen J; Astier A; Chatelut E
    Eur J Cancer; 2014 Aug; 50(12):2010-9. PubMed ID: 24889915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Individualized precision dosing approaches to optimize antimicrobial therapy in pediatric populations.
    Tu Q; Cotta M; Raman S; Graham N; Schlapbach L; Roberts JA
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1383-1399. PubMed ID: 34313180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
    Gotta V; Widmer N; Decosterd LA; Chalandon Y; Heim D; Gregor M; Benz R; Leoncini-Franscini L; Baerlocher GM; Duchosal MA; Csajka C; Buclin T
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1307-19. PubMed ID: 25297989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose Individualization of Oral Multi-Kinase Inhibitors for the Implementation of Therapeutic Drug Monitoring.
    Noda S; Morita SY; Terada T
    Biol Pharm Bull; 2022; 45(7):814-823. PubMed ID: 35786588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study.
    Cabel L; Blanchet B; Thomas-Schoemann A; Huillard O; Bellesoeur A; Cessot A; Giroux J; Boudou-Rouquette P; Coriat R; Vidal M; Saidu NEB; Golmard L; Alexandre J; Goldwasser F
    Fundam Clin Pharmacol; 2018 Feb; 32(1):98-107. PubMed ID: 29055166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study.
    Zuidema S; Desar IME; van Erp NP; Kievit W
    Br J Clin Pharmacol; 2019 Sep; 85(9):1994-2001. PubMed ID: 31112617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personalised antimicrobial dosing: standing on the shoulders of giants.
    Wallenburg E; Ter Heine R; Schouten JA; Brüggemann RJM
    Int J Antimicrob Agents; 2020 Sep; 56(3):106062. PubMed ID: 32574792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?
    Strik AS; Berends SE; Löwenberg M
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):885-891. PubMed ID: 31305158
    [No Abstract]   [Full Text] [Related]  

  • 30. Diversity of dose-individualization and therapeutic drug monitoring practices of platinum compounds: a review.
    Maillard M; Le Louedec F; Thomas F; Chatelut E
    Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):907-925. PubMed ID: 33016786
    [No Abstract]   [Full Text] [Related]  

  • 31. The role of therapeutic drug monitoring in the management of safety of anticancer agents: a focus on 3 cytotoxics.
    Levêque D; Becker G
    Expert Opin Drug Saf; 2019 Nov; 18(11):1009-1015. PubMed ID: 31478396
    [No Abstract]   [Full Text] [Related]  

  • 32. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
    Evelina Cardoso ; Guidi M; Khoudour N; Pascaline Boudou-Rouquette ; Fabre E; Tlemsani C; Arrondeau J; François Goldwasser ; Vidal M; Schneider MP; Wagner AD; Widmer N; Blanchet B; Csajka C
    Clin Ther; 2020 Jul; 42(7):1302-1316. PubMed ID: 32631634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
    Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
    Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.
    Terada T; Noda S; Inui K
    Pharmacol Ther; 2015 Aug; 152():125-34. PubMed ID: 25976912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic drug monitoring of cancer chemotherapy.
    Alnaim L
    J Oncol Pharm Pract; 2007 Dec; 13(4):207-21. PubMed ID: 18045780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.
    Westerdijk K; Desar IME; Steeghs N; van der Graaf WTA; van Erp NP;
    Br J Clin Pharmacol; 2020 Feb; 86(2):258-273. PubMed ID: 31782166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours.
    Goulooze SC; Galettis P; Boddy AV; Martin JH
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):209-16. PubMed ID: 27295055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Toward Personalized Cancer Therapy with Oral Molecular-targeted Agents].
    Yamaguchi H; Takasaki S; Kikuchi M; Kawasaki Y; Arai Y; Mano N
    Yakugaku Zasshi; 2019; 139(6):911-915. PubMed ID: 31155535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic drug monitoring of β-lactam antibiotics in the ICU.
    Dhaese S; Van Vooren S; Boelens J; De Waele J
    Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1155-1164. PubMed ID: 32597263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.
    Lucas CJ; Martin JH
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S78-S98. PubMed ID: 28921641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.